Hostname: page-component-7479d7b7d-q6k6v Total loading time: 0 Render date: 2024-07-13T13:26:56.118Z Has data issue: false hasContentIssue false
  • English
  • Français

The efficacy of a dose-escalated application of transdermal nicotine plus sulpiride in Tourette’s syndrome

Published online by Cambridge University Press:  16 April 2020

SM Dursun  and
MA Reveley
SM Dursun
Affiliation:
Department of Psychiatry, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, PO Box 65, Leicester, LE2 7LX, UK
MA Reveley
Affiliation:
Department of Psychiatry, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, PO Box 65, Leicester, LE2 7LX, UK
Get access

Summary

The addition of a dose-escalated regimen of transdermal nicotine patches (TNP) improved tics of a non-smoker patient with Tourette's syndrome, whose tics did not respond to sulpiride. This improvement, as assessed by the Yale Global Tic Severity Scale, lasted for up to 8 weeks, but not 16 weeks. An explanation for the efficacy of TNP is presented.

Keywords

Tourette’s syndrometicstreatmenttransdermal nicotine patch
Type
Short communication
Information
European Psychiatry , Volume 11 , Issue 4 , 1996 , pp. 204 - 206
Copyright
Copyright © Elsevier, Paris 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders 3rd edn revised (DSM-III-R) 1987 APA Washington, DCGoogle Scholar
Bannet, J, Belmaker, RHNew Directions in Tardive Dyskinesia Research 1983 Karger BaselGoogle Scholar
Davila, DG, Hurt, RD, Offord, KP, Harris, CD, Shepard, JWAcute effects of transdermal nicotine on sleep architecture, snoring and sleep-disordered breathing in non-smokers Am J Respir Crit Care Med 150 1994 469–47410.1164/ajrccm.150.2.8049831CrossRefGoogle Scholar
Dursun, SM, Reveley, MA, Bird, R, Stirton, FLong-lasting improvement of Tourette's syndrome with transdermal nicotine Lancet 344 1994 1577CrossRefGoogle Scholar
Gerlach, J, Reisby, N, Randup, ADopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia Psychopharmacologia 34 1974 21–35CrossRefGoogle ScholarPubMed
Leckman, JF, Riddle, MA, Hardin, MT, Ort, SI, Swartz, KL, Stevenson, J, Cohen, DJThe Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity J Am Acad Child Adolesc Psychiatry 28 1989 566–573CrossRefGoogle ScholarPubMed
McConville, BH, Sanberg, PR, Fogelson, MH, King, J, Cirino, P, Parker, KW, Norman, ABThe effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tics severity and frequency in Tourette's disorder Biol Psychiatry 31 1992 832–840CrossRefGoogle Scholar
Richelson, ENeuroleptic affinities for human brain receptors and their use in predicting adverse effects J Clin Psychiatry 45 1984 331–336Google ScholarPubMed
Sethy, VM, Vanwoert, MHModification of striatal acetylcholine concentration by dopamine receptor agonists and antagonists Res Commun Chem Pathol Pharmacol 8 1974 13–28Google ScholarPubMed
Silver, AA, Sanberg, PRTransdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome Lancet 342 1993 18210.1016/0140-6736(93)91392-YCrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.